Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Research Corporation Technologies (RCT) is a venture capital firm based in Tucson, Arizona, founded in 1987. The firm manages assets exceeding $500 million and focuses on early-stage funding for biomedical companies and technologies. RCT primarily invests in startups emerging from universities and research institutions worldwide.
RCT invests $500K to $5M in pre-seed, seed, and seed+ stage companies within the biotech and healthcare sectors. Their investment strategy emphasizes flexible, long-term funding options for technologies with the potential to become significant biomedical products. Key areas of interest include therapeutics, medical devices, and tools.
Notable companies backed by RCT include Therapeutic Human Polyclonals, Inc., which was acquired by Roche, and VasoNova, Inc., a medical device company. They also supported Option 3, a medical device development vehicle, and contributed to the development of anticancer drugs Cisplatin and Carboplatin, discovered at Michigan State University.
Submit your pitch through their form at rctech.com.
RCT often leads funding rounds, particularly in the early stages of investment, to ensure they can provide the necessary support for technology development.
RCT is open to follow-on investments, especially for companies that demonstrate significant progress and potential for growth in the biomedical field.
RCT manages a fund size of $500 million, allowing them to make substantial investments in promising biomedical startups.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.